{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:57:42Z","timestamp":1700780262926},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00108-014-3594-7","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T11:03:24Z","timestamp":1428577404000},"page":"333-343","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronische myeloische Leuk\u00e4mie"],"prefix":"10.1007","volume":"56","author":[{"given":"A.","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Eigendorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"key":"3594_CR1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"Hehlmann","year":"2007","unstructured":"Hehlmann R et\u00a0al (2007) Chronic myeloid leukaemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"3594_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","volume":"22","author":"Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22:295\u2013302","journal-title":"Best Pract Res Clin Haematol"},{"key":"3594_CR3","first-page":"49","volume":"25","author":"Sokal","year":"1988","unstructured":"Sokal JE et\u00a0al (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25:49\u201361","journal-title":"Semin Hematol"},{"key":"3594_CR4","doi-asserted-by":"crossref","unstructured":"Hasford J et\u00a0al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J\u00a0Natl Cancer Inst 90:850\u2013858","DOI":"10.1093\/jnci\/90.11.850"},{"key":"3594_CR5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"Hasford","year":"2011","unstructured":"Hasford J et\u00a0al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060\u00a0patients with CML on imatinib treatment: the EUTOS score. Blood 118:686\u2013692","journal-title":"Blood"},{"key":"3594_CR6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"Baccarani","year":"2013","unstructured":"Baccarani M et\u00a0al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"3594_CR7","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG et\u00a0al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N\u00a0Engl J Med 348:994\u20131004","DOI":"10.1056\/NEJMoa022457"},{"key":"3594_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"Hochhaus","year":"2009","unstructured":"Hochhaus A et\u00a0al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"3594_CR9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"Weisberg","year":"2007","unstructured":"Weisberg E et\u00a0al (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:345\u2013356","journal-title":"Nat Rev Cancer"},{"key":"3594_CR10","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"Larson","year":"2012","unstructured":"Larson RA et\u00a0al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203","journal-title":"Leukemia"},{"key":"3594_CR11","first-page":"Abstract","volume":"124","author":"Larson","year":"2014","unstructured":"Larson R et\u00a0al (2014) Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd. Blood 124: Abstract #4541","journal-title":"Blood"},{"key":"3594_CR12","doi-asserted-by":"crossref","unstructured":"La Ros\u00e9e P et\u00a0al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 92:1345\u20131350","DOI":"10.1007\/s00277-013-1769-2"},{"key":"3594_CR13","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kantarjian H (2013) The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J\u00a0Cancer Res Clin Oncol 139:1971\u20131984","DOI":"10.1007\/s00432-013-1488-z"},{"key":"3594_CR14","first-page":"Abstract","volume":"124","author":"Cortes","year":"2014","unstructured":"Cortes J et\u00a0al (2014) Final study results of the phase\u00a03 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood 124: Abstract #152","journal-title":"Blood"},{"key":"3594_CR15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"Br\u00fcmmendorf","year":"2015","unstructured":"Br\u00fcmmendorf TH et\u00a0al (2015) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69\u201381","journal-title":"Br J Haematol"},{"key":"3594_CR16","doi-asserted-by":"crossref","unstructured":"Cortes JE et\u00a0al (2013) A phase\u00a02 trial of ponatinib in Philadelphia chromosome-positive leukemias. N\u00a0Engl J Med 369:1783\u20131796","DOI":"10.1056\/NEJMoa1306494"},{"key":"3594_CR17","first-page":"Abstract","volume":"124","author":"Lipton","year":"2014","unstructured":"Lipton JH et\u00a0al (2014) EPIC: a phase\u00a03 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood 124: Abstract #519","journal-title":"Blood"},{"key":"3594_CR18","doi-asserted-by":"crossref","unstructured":"Hehlmann R et\u00a0al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J\u00a0Clin Oncol 29:1634\u20131642","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"3594_CR19","doi-asserted-by":"crossref","unstructured":"Cortes JE et\u00a0al (2010) Phase\u00a0III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J\u00a0Clin Oncol 28:424\u2013430","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"3594_CR20","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2014-01-546705","volume":"123","author":"Hochhaus","year":"2014","unstructured":"Hochhaus A (2014) Optimizing tolerability of TKI therapy in CML. Blood 123:1284\u20131285","journal-title":"Blood"},{"key":"3594_CR21","doi-asserted-by":"crossref","unstructured":"Preudhomme C (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N\u00a0Engl J Med 363:2511\u20132521","DOI":"10.1056\/NEJMoa1004095"},{"key":"3594_CR22","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"Simonsson","year":"2011","unstructured":"Simonsson B et\u00a0al (2011) Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118:3228\u20133235","journal-title":"Blood"},{"key":"3594_CR23","doi-asserted-by":"crossref","unstructured":"Burchert A et\u00a0al (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J\u00a0Clin Oncol 28:1429\u20131435","DOI":"10.1200\/JCO.2009.25.5075"},{"key":"3594_CR24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon","year":"2010","unstructured":"Mahon FX et\u00a0al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"3594_CR25","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1182\/blood.V124.21.151.151","volume":"124","author":"Mahon","year":"2014","unstructured":"Mahon FX et\u00a0al (2014) Interim analysis of a pan European Stop Tyrosine Kinase Inhibitor Trial in chronic myeloid leukemia: the EURO-SKI study. Blood 124: Abstract #151","journal-title":"Blood"},{"key":"3594_CR26","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","volume":"28","author":"Schmidt","year":"2014","unstructured":"Schmidt M et\u00a0al (2014) Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 28:2292\u20132299","journal-title":"Leukemia"},{"key":"3594_CR27","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"Cross","year":"2012","unstructured":"Cross NC et\u00a0al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175","journal-title":"Leukemia"},{"key":"3594_CR28","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"Hanfstein","year":"2012","unstructured":"Hanfstein B et\u00a0al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"key":"3594_CR29","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"Hanfstein","year":"2014","unstructured":"Hanfstein B et\u00a0al (2014) Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28:1988\u20131992","journal-title":"Leukemia"},{"key":"3594_CR30","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321\u20131331","journal-title":"Leukemia"},{"key":"3594_CR31","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"Soverini","year":"2011","unstructured":"Soverini S et\u00a0al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208\u20131215","journal-title":"Blood"},{"key":"3594_CR32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"Kantarjian","year":"2011","unstructured":"Kantarjian HM et\u00a0al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141\u20131145","journal-title":"Blood"},{"key":"3594_CR33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"le","year":"2012","unstructured":"le Coutre PD et\u00a0al (2012) Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189\u20131194","journal-title":"Leukemia"},{"key":"3594_CR34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"Giles","year":"2012","unstructured":"Giles FJ et\u00a0al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"3594_CR35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"Hochhaus","year":"2008","unstructured":"Hochhaus A et\u00a0al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"3594_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","unstructured":"Shah NP et\u00a0al (2010) Potent, transient inhibition of BCR-ABL with dasatinib 100\u00a0mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232\u2013240","journal-title":"Haematologica"},{"key":"3594_CR37","doi-asserted-by":"crossref","unstructured":"Apperley JF et\u00a0al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START\u00a0a trial. J\u00a0Clin Oncol 27:3472\u20133479","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"3594_CR38","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"Cortes","year":"2007","unstructured":"Cortes J et\u00a0al (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207\u20133213","journal-title":"Blood"},{"key":"3594_CR39","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"Cortes","year":"2011","unstructured":"Cortes JE et\u00a0al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118:4567\u20134576","journal-title":"Blood"},{"key":"3594_CR40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","volume":"25","author":"Jabbour","year":"2011","unstructured":"Jabbour E et\u00a0al (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:201\u2013210","journal-title":"Leukemia"},{"key":"3594_CR41","doi-asserted-by":"crossref","unstructured":"Hughes T et\u00a0al (2009) Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J\u00a0Clin Oncol 27:4204\u20134210","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"3594_CR42","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"M\u00fcller","year":"2009","unstructured":"M\u00fcller MC et\u00a0al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944\u20134953","journal-title":"Blood"},{"key":"3594_CR43","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"Saussele","year":"2010","unstructured":"Saussele S et\u00a0al (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study\u00a0IV. Blood 115:1880\u20131885","journal-title":"Blood"},{"key":"3594_CR44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737\u2013747","journal-title":"Blood"},{"key":"3594_CR45","doi-asserted-by":"crossref","first-page":"Abstract","DOI":"10.1182\/blood.V124.21.398.398","volume":"124","author":"Wylie","year":"2014","unstructured":"Wylie A et\u00a0al (2014) ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 124: Abstract #398","journal-title":"Blood"},{"key":"3594_CR46","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"M\u00fcller","year":"2009","unstructured":"M\u00fcller MC (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957\u20131963","journal-title":"Leukemia"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3594-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-014-3594-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-014-3594-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T17:33:50Z","timestamp":1598895230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-014-3594-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1007\/s00108-014-3594-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]}}}